

RNS Number : 7242B
Haleon PLC
02 October 2025



Haleon plc: Transaction in own shares and update on the Buyback Programme

02 October 2025: Haleon plc (the "Company" or "Haleon") today announces the purchase of 1,561,229 ordinary shares of £0.01 each in the Company (the "Shares") under the second tranche of its share buyback programme announced on 31 July 2025.

	London Stock Exchange	CBOE (UK)/BXE	CBOE (UK)/CXE
Date of purchase:	01 October 2025	01 October 2025	01 October 2025
Number of Shares purchased:	1,561,229	-	-
Highest price paid per Share (p):	337.5000	-	-
Lowest price paid per Share (p):	331.9000	-	-
Volume weighted average price paid per Share (p):	335.0704	-	-

The Company intends to hold the purchased shares as treasury shares.

Following the settlement of the above, the Company's registered share capital is 8,952,353,648 ordinary shares of £0.01 each, of which 45,962,012 are held as treasury shares. Therefore, the number of ordinary shares with voting rights is 8,906,391,636 and this figure may be used by shareholders to determine if they are required to notify their interest, or a change to their interest, in Haleon under the FCA's Disclosure Guidance and Transparency Rules.

In accordance with Article 5(1)(b) of Regulation (EU) No 596/2014 as it applies in the UK (the Market Abuse Regulation), a full breakdown of the individual trades is available at the link below:

http://www.ms-pdf.londonstockexchange.com/ms/7242B_1-2025-10-1.pdf

This announcement does not constitute, or form part of, an offer or any solicitation of an offer for securities in any jurisdiction.

This announcement and individual trade breakdown will also be available on the Company's website at: www.haleon.com/investors.

Completion of the Buyback Programme

Following the above transaction, Haleon has completed the final tranche of the Buyback Programme announced on 28 March 2025.

Since the start of the year, including the Shares purchased from Pfizer, the Company has repurchased 175,806,525 Shares, of which 131,372,271 were cancelled and 44,434,254 were held as treasury shares.

Enquiries

Investors

Jo Russell +44 7787 392441
Rakesh Patel +44 7552 484646
Email: investor-relations@haleon.com

Media

Zoë Bird +44 7736 746167
Victoria Durman +44 7894 505730
Email: corporate.media@haleon.com

About Haleon

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as *Advil*, *Centrum*, *Otrivin*, *Panadol*, *parodontax*, *Polident*, *Sensodyne*, *Theraflu* and *Voltaren* - are built on trusted science, innovation and deep human understanding.

For more information, please visit www.haleon.com.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@seg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

POSPKDBNCBDDOKK